Julie Blaising

Roche (Switzerland)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

ÈP

Ève-Isabelle Pécheur

Centre de Recherche en Cancérologie de Lyon

Uwe Grether

Roche (Switzerland)

Bernd Kuhn

Roche (Switzerland)

Mihayl Varbanov

Université de Lorraine

Mario van der Stelt

Leiden University

Stephen J. Polyak

University of Washington

Arnaud Favier

Université Claude Bernard Lyon 1

Marc Nazaré

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

Florence Ruggiero

Université Claude Bernard Lyon 1

Christophe Place

École Normale Supérieure de Lyon

Cooperative Institutions

Roche (Switzerland)

Centre National de la Recherche Scientifique

ETH Zurich

Université Claude Bernard Lyon 1

Inserm

École Normale Supérieure de Lyon

Centre de Recherche en Cancérologie de Lyon

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

University of Cambridge

Board of the Swiss Federal Institutes of Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

MAGL inhibition: A novel treatment option for combating inflammatory disease?

Open Access Government (2024)

Uwe Grether Julie Blaising

MAGL inhibition: A novel treatment option for combating inflammatory disease? Pharma researchers Uwe Grether and Julie Blaising from F. 48-La Roche Ltd. highlight the vast therapeutic potential of MAGL inhibition for central and peripheral diseases. The endocannabinoid system (ECS) is an important lipid signalling system that is highly conserved among vertebrates. It plays a key role in many human health and disease states.(1) Key components of the ECS are the endocannabinoids (eCBs), in particular 2-arachidonylglycerol (2-AG) and N-arachidonoylethanolamine (AEA). The eCBs bind to and activate the type-1 and type-2 cannabinoid receptors (CB1R and CB2R, respectively), which are highly important targets for treating multiple human diseases ranging from metabolic indications to neurodegenerative disorders.(2)

10.56367/oag-041-11209

Cite

Citations (0)

Lipids ‒ A key for hepatitis C virus entry and a potential target for antiviral strategies

Biochimie (2012)

Julie Blaising Ève-Isabelle Pécheur

Viral life cycle

Lipid droplet

Infectivity

10.1016/j.biochi.2012.07.016

Cite

Citations (34)

Fluorescent lipid-polymer probes for far-red/NIR and dSTORM optical imaging of enveloped virus particles

Arnaud Favier William Lacour Salim Adjili Julie Blaising Timothée Bresson

Source

Cite

Citations (0)

Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo

Molecular Therapy — Nucleic Acids (2018)

Hassan Javanbakht H. Mueller Johanna Walther Xue Zhou Anaïs Lopez

Chronic hepatitis B infection (CHB) is an area of high unmet medical need. Current standard-of-care therapies only rarely lead to a functional cure, defined as durable hepatitis B surface antigen (HBsAg) loss following treatment. The goal for next generation CHB therapies is to achieve a higher rate of functional cure with finite treatment duration. To address this urgent need, we are developing liver-targeted single-stranded oligonucleotide (SSO) therapeutics for CHB based on the locked nucleic acid (LNA) platform. These LNA-SSOs target hepatitis B virus (HBV) transcripts for RNase-H-mediated degradation. Here, we describe a HBV-specific LNA-SSO that effectively reduces intracellular viral mRNAs and viral antigens (HBsAg and HBeAg) over an extended time period in cultured human hepatoma cell lines that were infected with HBV with mean 50% effective concentration (EC50) values ranging from 1.19 to 1.66 μM. To achieve liver-specific targeting and minimize kidney exposure, this LNA-SSO was conjugated to a cluster of three N-acetylgalactosamine (GalNAc) moieties that direct specific binding to the asialoglycoprotein receptor (ASGPR) expressed specifically on the surface of hepatocytes. The GalNAc-conjugated LNA-SSO showed a strikingly higher level of potency when tested in the AAV-HBV mouse model as compared with its non-conjugated counterpart. Remarkably, higher doses of GalNAc-conjugated LNA-SSO resulted in a rapid and long-lasting reduction of HBsAg to below the detection limit for quantification, i.e., by 3 log10 (p < 0.0003). This antiviral effect depended on a close match between the sequences of the LNA-SSO and its HBV target, indicating that the antiviral effect is not due to non-specific oligonucleotide-driven immune activation. These data support the development of LNA-SSO therapeutics for the treatment of CHB infection.

HBeAg

Asialoglycoprotein receptor

Hepatitis B

10.1016/j.omtn.2018.02.005

Cite

Citations (59)

Therapeutic potential of the endocannabinoid system to treat chronic pain in inflammatory disease

Open Access Government (2024)

Julie Blaising Phil E M Smith

Therapeutic potential of the endocannabinoid system to treat chronic pain in inflammatory disease Pharma researchers Julie Blaising and Philip Smith from F. Hoffmann-La Roche Ltd. discuss the endocannabinoid system as a pathway to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and endometriosis. The endocannabinoid system (ECS) is a complex system that comprises the cannabinoid receptors 1 and 2 (CB1 and CB2, respectively), endocannabinoid (EC) ligands, and enzymes involved in the synthesis and degradation of endocannabinoids. (1) It is broadly expressed in the body and modulates physiology and immunity. (2, 3)

10.56367/oag-042-11209

Cite

Citations (0)

Arbidol as a broad-spectrum antiviral: An update

Antiviral Research (2014)

Julie Blaising Stephen J. Polyak Ève-Isabelle Pécheur

Broad spectrum

10.1016/j.antiviral.2014.04.006

Cite

Citations (457)

Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking

Antiviral Research (2013)

Julie Blaising Pierre Lévy Stephen J. Polyak Megan L. Stanifer Steeve Boulant

10.1016/j.antiviral.2013.08.008

Cite

Citations (86)

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects

CHIMIA International Journal for Chemistry (2024)

Johannes D. Aebi Kenneth Atz Simon M. Ametamey Jörg Benz Julie Blaising

The endocannabinoid system (ECS) is a critical regulatory network composed of endogenous cannabinoids (eCBs), their synthesizing and degrading enzymes, and associated receptors. It is integral to maintaining homeostasis and orchestrating key functions within the central nervous and immune systems. Given its therapeutic significance, we have launched a series of drug discovery endeavors aimed at ECS targets, including peroxisome proliferator-activated receptors (PPARs), cannabinoid receptors types 1 (CB1R) and 2 (CB2R), and monoacylglycerol lipase (MAGL), addressing a wide array of medical needs. The pursuit of new therapeutic agents has been enhanced by the creation of specialized labeled chemical probes, which aid in target localization, mechanistic studies, assay development, and the establishment of biomarkers for target engagement. By fusing medicinal chemistry with chemical biology in a comprehensive, translational end-to-end drug discovery strategy, we have expedited the development of novel therapeutics. Additionally, this strategy promises to foster highly productive partnerships between industry and academia, as will be illustrated through various examples.

Drug Development

10.2533/chimia.2024.499

Cite

Citations (0)

Protein kinases for combating inflammatory disease

Open Access Government (2024)

Julie Blaising

Protein kinases for combating inflammatory disease Julie Blaising, Discovery Project Leader in Immunology at F. Hoffmann-La Roche Ltd, tells us why protein kinases are an effective target for treating many chronic inflammatory disorders. Kinases are enzymes responsible for protein phosphorylation. The human kinome consists of about 518 protein kinases and is classified according to the amino acid residue that it phosphorylates. (1) Kinases are expressed in many cell types and are involved in cell signaling, which leads to key physiological processes such as cell growth, proliferation, metabolism, and regulation of immune responses. (1, 2) Due to their central role in cellular processes, they are also associated with many diseases.

10.56367/oag-043-11209

Cite

Citations (0)

Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx

Cellular Microbiology (2016)

Boyan Grigorov Emma Reungoat Alice Gentil Dit Maurin Mihayl Varbanov Julie Blaising

The hepatitis C virus (HCV) infects hepatocytes after binding to heparan sulfate proteoglycans, in particular Syndecan-1, followed by recognition of the tetraspanin CD81 and other receptors. Heparan sulfate proteoglycans are found in a specific microenvironment coating the hepatocyte surface called the glycocalyx and are receptors for extracellular matrix proteins, cytokines, growth factors, lipoproteins, and infectious agents. We investigated the mutual influence of HCV infection on the glycocalyx and revealed new links between Syndecan-1 and CD81. Hepatocyte infection by HCV was inhibited after knocking down Syndecan-1 or Xylosyltransferase 2, a key enzyme of Syndecan-1 biosynthesis. Simultaneous knockdown of Syndecan-1 and CD81 strongly inhibited infection, suggesting their cooperative action. At early infection stages, Syndecan-1 and virions colocalized at the plasma membrane and were internalized in endosomes. Direct interactions between Syndecan-1 and CD81 were revealed in primary and transformed hepatocytes by immunoprecipitation and proximity ligation assays. Expression of Syndecan-1 and Xylosyltransferase 2 was altered within days post-infection, and the remaining Syndecan-1 pool colocalized poorly with CD81. The data indicate a profound reshuffling of the hepatocyte glycocalyx during HCV infection, possibly required for establishing optimal conditions of viral propagation.

Syndecan 1

CD81

Glycocalyx

Asialoglycoprotein receptor

Tetraspanin

10.1111/cmi.12711

Cite

Citations (32)